KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Receivables - Net: 2010-2024

Historic Receivables - Net for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to $154.5 million.

  • Emergent BioSolutions' Receivables - Net rose 23.25% to $149.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.5 million, marking a year-over-year increase of 23.25%. This contributed to the annual value of $154.5 million for FY2024, which is 19.11% down from last year.
  • According to the latest figures from FY2024, Emergent BioSolutions' Receivables - Net is $154.5 million, which was down 19.11% from $191.0 million recorded in FY2023.
  • Emergent BioSolutions' 5-year Receivables - Net high stood at $278.9 million for FY2021, and its period low was $154.5 million during FY2024.
  • Its 3-year average for Receivables - Net is $168.2 million, with a median of $159.2 million in 2022.
  • Per our database at Business Quant, Emergent BioSolutions' Receivables - Net increased by 20.79% in 2021 and then crashed by 42.92% in 2022.
  • Emergent BioSolutions' Receivables - Net (Yearly) stood at $230.9 million in 2020, then climbed by 20.79% to $278.9 million in 2021, then crashed by 42.92% to $159.2 million in 2022, then grew by 19.97% to $191.0 million in 2023, then decreased by 19.11% to $154.5 million in 2024.